Results 61 to 70 of about 85,814 (252)
Pharmacology Research & Perspectives, 2020 α1‐adrenoceptor antagonists are widely used for hypertension (eg, doxazosin) and benign prostatic hypertrophy (BPH, eg, tamsulosin). Some antidepressants and antipsychotics have been reported to have α1 affinity.
Richard G. W. Proudman +2 more
doaj +1 more source
, 1981 In the rat, suitable oral doses of tricyclic antidepressants (amitriptyline 20 mg kg−1, imipramine, desipramine 2·5 mg kg−1) are able to antagonize the increase of cardiac levels of intravenous tyramine after a pharmacologically active dose (3·5 mg kg−1 ...
M STROLIN BENEDETTI, N SONTAG, P DOSTERT
core +1 more source
British Journal of Haematology, EarlyView.Summary Preclinical and clinical studies suggest that selective serotonin reuptake inhibitors (SSRIs) can stimulate haematopoiesis by promoting proliferation and mobilization of haematopoietic stem and progenitor cells, but whether SSRI use influences myeloid malignancy risk remains unclear.
Katrine Mose +5 more
wiley +1 more source
Tricyclic antidepressants are effective for managing depression and other disorders. However, they can cause adverse reactions due to their anticholinergic properties, with the risk of such events increasing with age.
González Burgos, Elena María +3 more
core +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons
Frontiers in Physiology, 2014 Amitriptyline, a tricyclic antidepressant, has been used in the clinic to treat a number of disorders, in particular major depression and neuropathic pain.
Nadine eBeckmann +4 more
doaj +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
British Journal of Pharmacology, EarlyView.Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux +26 more
wiley +1 more source
, 2007 This is the first of two chapters describing how drugs which are not usually classed as analgesics can be used to treat neuropathic pain. Chapter 8 is about tricyclic antidepressants (TCAs) and Chapter 9 about anticonvulsants. There is also a table which
Simon Davies
core +1 more source